Effect of low and high dose melagatran and other antithrombotic drugs on platelet aggregation

Journal of Thrombosis and Thrombolysis

Volumn 25, Issue 2, 2008, Pages 198-203

  Soslau, Gerald ^a   Ando, Aimee ^a   Floyd, La Toya ^a   Hong, Tom ^a   Mathew, Lynn ^a   Yen, Yvonne ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Anti thrombotic; In vitro; Melagatran; Platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; BETA THROMBIN; GAMMA THROMBIN; GLYCOPROTEIN IB ALPHA; HEPARIN; HIRUDIN; MELAGATRAN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; LOW DRUG DOSE; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; HUMANS; PLATELET AGGREGATION; THROMBIN;

EID: 42549092982     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0085-x     Document Type: Article

References (15)

1. Ansell J (2005) Long-term anticoagulation: The prospects for alternatives to warfarin. Semin Vasc Surg 18:134-138
2. Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halpern F, Horrow J (2006) Comparison of bleeding in patients with nonvascular atrial fibrillation treated with ximelagatran or warfarin: Assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med 166:853-859
3. Soslau G, Class R, Morgan DA, Foster C, Lord St, Marchese P, Ruggeri ZM (2001) Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. J Biol Chem 276:21173-21183
4. Soslau G, Goldenberg SJ, Class R, Jameson B (2004) Differential activation and inhibition of human platelet thrombin receptors by structurally distinct α-,β- and γ-thrombin. Platelets 15:155-166
5. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Egl M, Mattsson C, Deinum J, Pehrsson S, Karlsson E, Nilsson A, Sorensen H (1998) Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 79:110-118
6. Ho SJ, Brighton TA (2006) Ximelagatran: Direct thrombin inhibitor. Vasc Health Risk Manage 2:49-58
7. Johnson PH (1994) Hirudin: Clinical potential of a thrombin inhibitor. Annu Rev Med 45:165-177
8. Matthai WH Jr, Hursting MJ, Lewis BE, Kelton JG (2005) Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb Res 116:121-126
9. Mousa SA (2006) Role of current and emerging antithrombotics in thrombosis and cancer. Drugs Today (Barc) 42:331-350
10. Nylander S, Mattsson C (2003) Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action. Blood Coagul Fibrinolysis 14:159-167
11. Di Nisio M, Middeldorp S, Büller HR (2005) Direct thrombin inhibitors. N Engl J Med 353:1028-1040
12. Soslau G, Goldenberg SJ, Class R (2002) Differential activation and inhibition of human platelet thrombin receptors by structurally distinct α-,β- and γ-thrombin. Blood 100:255a
13. Soslau G, Goldenberg SJ, Navas E, Mattsson C, Nylander S (2002) (Xi) Melagatran inhibition of alpha-thrombin GPlb and beta, gamma-thrombin-PAR-4 platelet aggregation pathways. Blood 100:255a
14. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Mattsson C, Deinum J, Pehrsson S, Karlsson O, Nilsson A, Sorensen H (1998) Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 79:110-118
15. Carlsson SC, Mattsson C, Eriksson UG, Sarich TC, Wahlander K, Eliasson A, Karlson BW, Sheth SB, Held P (2005) A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays. Thromb Res 115:9-18